CFDA and Zhejiang Provincial Bureau sign cooperation agreement on deepening drug review system reform and innovative services

Source: in the morning of February 2, 2018, the drug review center of the State Food and Drug Administration and the Provincial Bureau signed the "cooperation agreement on deepening the reform of drug review system and innovation services" in Hangzhou Shao Yuanchang, deputy director of the Provincial Bureau, introduced the main contents of the agreement, and Xu Jiaqi, director of the drug audit center of the State Administration, and Chen Shifei, director of the Provincial Bureau, signed and addressed the agreement on behalf of both parties The signing of this cooperation agreement aims to thoroughly implement the spirit of the opinions on deepening the reform of the review and approval system and encouraging the innovation of pharmaceutical and medical devices issued by the central office and the state office, further deepen the reform of the drug review system, promote the complementary advantages between the national drug technical review ability and the Provincial Bureau's technical review, strengthen the team building, enhance the innovation service ability, and better serve the pharmaceutical innovation of our province New and industrial development According to the agreement, the two sides will give full play to their advantages and characteristics in the field of drug technology review, cooperate in capacity-building, infrastructure construction, team building and other aspects, and explore the construction of a review system to promote drug innovation Director Xu Jiaqi first expressed his gratitude to Zhejiang Provincial Bureau for sending a team to work together with the center personnel to solve the backlog of review during the difficult period of serious backlog of pending varieties in the drug review center of the general administration He pointed out that in the next step of evaluation system construction, we should promote cooperation with Zhejiang Provincial Bureau, enhance the capacity of both sides, accelerate the innovation policy of promoting the reform of drug evaluation and approval system to take root in Zhejiang, and constantly refine the cooperation content and improve the working mechanism By sending each other's personnel to the other side for study and training, we will cultivate a group of high-quality and professional drug review talents and innovation teams for both sides Director Chen Shifei pointed out that drug safety and efficacy are an important guarantee for building a well-off society in an all-round way Under the correct leadership of the Party group of the General Administration, the drug evaluation center of the General Administration has carried out a series of reform of drug evaluation and approval system and solved the long-term unsolved problems The signing of this agreement is of great significance to further deepen the reform of drug review system and promote the construction of Drug Technology Review Capacity in our province As a major province of medicine, Zhejiang is leading the country in the export of drugs and APIs, and its innovation and development situation in recent years is gratifying It is hoped that the drug audit center of the General Administration will give full play to the advantages of professional technology, talent team, information resources, etc., and give more guidance and help to drug supervision and new drug research and development in Zhejiang Province We look forward to fruitful cooperation for the benefit of the people!